(Q21183974)

16 August 2022

4

Aron C Eklund

Aron C

Eklund

1 reference

16 August 2022

3

Marco Gerlinger

Marco

Gerlinger

1 reference

16 August 2022

19

Hansjuergen Volkmer

Hansjuergen

Volkmer

1 reference

16 August 2022

23

Zoltan Szallasi

Zoltan

Szallasi

1 reference

16 August 2022

6

Gordon Stamp

Gordon

Stamp

1 reference

16 August 2022

1

Charles Swanton

Charles

Swanton

1 reference

16 August 2022

12

Laurence Albiges

Laurence

Albiges

1 reference

16 August 2022

10

Bernard Escudier

Bernard

Escudier

1 reference

16 August 2022

Benoit Beuselinck

13

Benoit

Beuselinck

1 reference

16 August 2022

9

P Andrew Futreal

P Andrew

Futreal

1 reference

16 August 2022

21

Barbara

Nicke

Barbara Nicke

1 reference

16 August 2022

James M Larkin

2

James M

Larkin

1 reference

16 August 2022

Michael Howell

5

Michael

Howell

1 reference

16 August 2022

Martin Gore

8

Martin

Gore

1 reference

16 August 2022

Fabrice Andre

11

Fabrice

Andre

1 reference

16 August 2022

Stephane Oudard

14

Stephane

Oudard

1 reference

16 August 2022

Jens Hoffmann

15

Jens

Hoffmann

1 reference

16 August 2022

Balázs Gyorffy

16

Balázs

Gyorffy

1 reference

16 August 2022

Chris J Torrance

17

Chris J

Torrance

1 reference

16 August 2022

Karen A Boehme

18

Karen A

Boehme

1 reference

16 August 2022

Luisella Toschi

20

Luisella

Toschi

1 reference

16 August 2022

Marlene Beck

22

Marlene

Beck

1 reference

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

16 August 2022

language of work or name

English

0 references

publication date

2010

0 references

published in

Genome Medicine

0 references

volume

2

0 references

issue

8

0 references

page(s)

53

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Modes of resistance to anti-angiogenic therapy

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Molecular markers of early Parkinson's disease based on gene expression in blood

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

A quantitative analysis of kinase inhibitor selectivity

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Sorafenib in advanced clear-cell renal-cell carcinoma

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Why do cancers have high aerobic glycolysis?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

mTOR and cancer: insights into a complex relationship

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Biomarkers of response and resistance to antiangiogenic therapy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Chromosomal instability determines taxane response

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Systematic identification of gene activities promoting hypoxic death

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

VEGF-targeted therapy: mechanisms of anti-tumour activity.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Molecular basis for sunitinib efficacy and future clinical development

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Regulation of DNA repair in hypoxic cancer cells

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Estimates of the cancer incidence and mortality in Europe in 2006.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Targeting von Hippel-Lindau pathway in renal cell carcinoma

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Antiangiogenic therapy and tumor progression

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Angiogenesis and apoptosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Modulation of cell death in the tumor microenvironment

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Outcome signature genes in breast cancer: is there a unique set?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Finding the weakness in cancer.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Effect of p53 status on tumor response to antiangiogenic therapy.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2945010

Patient survival for all cancers combined as indicator of cancer control in Europe

29 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20701793

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Costly cancer drugs trigger proposals to modify clinical trial design

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20701793

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prediction of cancer outcome with microarrays: a multiple random validation strategy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20701793

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/GM174

0 references